Returning Home After Mantle Cell Lymphoma Treatment in China: Making Follow-Up Work

Leaving a Chinese hospital does not describe a single stage of mantle cell lymphoma care. One patient may have completed treatment and entered remission. Another may still be taking an oral medicine, receiving maintenance, or recovering from a transplant or CAR-T infusion. Their monitoring needs will differ even if each discharge letter contains the same brief instruction to arrange regular follow-up.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

The handover should state whether the current approach is watchful waiting, follow-up after treatment, maintenance, continuing targeted therapy, or post-transplant or post-CAR-T care. Include the date and conclusion of the latest response assessment, together with any finding that remains unresolved. Complete remission does not end the need for lymphoma follow-up because relapse can occur over a prolonged period.[1]
Review the exact product, remaining supply, prescription requirements, and local source before travel. A medicine available in China may not be supplied in the same formulation, for the same indication, or under the same payment arrangements in the home country. A pharmacist and prescriber should help resolve these questions before the current supply runs low.
A new lump or abnormal result should lead to local clinical assessment and any necessary investigation. Share the findings with the Chinese team if another opinion or return visit may be useful. One abnormal marker is not a sufficient basis for ordering the next drug, and anxiety about recurrence is not a reason to repeat every previous test without discussing its purpose.

Quick answer

Full guide

The practical task is to turn that instruction into an agreed arrangement before the journey home. A result needs someone to interpret it. A continuing prescription needs a clinician able to issue it. A new symptom needs an accessible local response. The patient and family can help check these arrangements, but should not be left to resolve conflicting instructions between hospitals on their own.

Name the phase of care at the point of transfer

The handover should state whether the current approach is watchful waiting, follow-up after treatment, maintenance, continuing targeted therapy, or post-transplant or post-CAR-T care. Include the date and conclusion of the latest response assessment, together with any finding that remains unresolved. Complete remission does not end the need for lymphoma follow-up because relapse can occur over a prolonged period.[1]

For someone still taking treatment, returning home may mainly change the location of care. Clarify who will prescribe, who will review laboratory results, and who can decide whether a medicine needs to be interrupted or restarted. Feeling well enough to manage tablets at home does not remove the need to check tolerability and possible interactions.

Watchful waiting also requires a defined plan. Reviews assess whether the disease remains suitable for that approach and whether symptoms or findings have changed. A previous decision that immediate treatment was unnecessary should not be interpreted as permission to ignore a new problem until a distant appointment.

Convert a general interval into actual appointments

The 2025 EHA–EU MCL guideline describes relatively frequent assessment early after first-line systemic treatment, with longer intervals later and generally continuing follow-up. Its detailed framework describes reviews every three to four months for two years, every six months for the following three years, and annually thereafter. This is a clinical reference, not a schedule that every patient should apply unchanged. Active treatment, high-risk disease, recent complications, or cellular therapy may require different monitoring.[1]

Before discharge, enter the next agreed review on a calendar and identify when any preceding tests should be performed. Check local availability and reporting time. If discussion with the Chinese team is part of the plan, allow for the method of communication and time-zone difference. A test that cannot be completed as expected should prompt an early scheduling discussion rather than an unexplained missed review.

The calendar may also need separate entries for prescription renewal, maintenance infusions, line care, or another specialty appointment. Those events need not occur on the same day. Reducing the entire plan to a visit every few months can conceal continuing treatment tasks between the larger lymphoma assessments.

Use each review to examine changes, not just scans

Prepare a brief account of new or worsening symptoms and daily function. Relevant changes can include fever, sweating at night, weight change, abdominal discomfort, a new lump, or reduced ability to carry out usual activities. Note when the change began, whether it persists, and whether treatment changed around the same time. This helps the clinician assess the problem without asking the family to diagnose relapse.

Imaging should answer a clinical question. The EHA guideline does not recommend PET-CT as routine surveillance in an otherwise asymptomatic patient. The choice and frequency of other imaging depend on the care plan. A review without a PET scan can therefore be entirely appropriate, while a concerning new finding may justify assessment before the next planned imaging date.[1]

Keep access to the important end-of-treatment reports and images for comparison. A single blood count, LDH value, or change in a measured node does not allow the family to settle the diagnosis. The local team needs to consider the pattern, the patient's history, and whether additional investigation will change management.

Assign responsibility for receiving results

Agree who will review routine blood tests and imaging first, what should be shared with the Chinese center, and which official channel should be used. NCI encourages a treatment summary and follow-up plan that identify the care required after treatment.[2] For an international patient, the plan should name an accessible local service rather than rely entirely on a general contact address at the distant hospital.

When sending an update, identify the date of the examination, the treatment being taken, and the decision on which advice is requested. A collection of unlabelled photographs makes it harder to recognize the current issue. If the hospital says a particular decision requires an in-person assessment, arrange that appropriately; submitting documents does not itself create a new medical instruction.

Keep a separate list of pending pathology, cultures, or molecular results. Record who will obtain them and communicate the conclusion. A patient can otherwise return home with the impression that the evaluation is complete while a clinically relevant result is still outstanding. If the original plan cannot be delivered locally, the two teams should identify a workable alternative.

Make continuing medication and maintenance feasible

Review the exact product, remaining supply, prescription requirements, and local source before travel. A medicine available in China may not be supplied in the same formulation, for the same indication, or under the same payment arrangements in the home country. A pharmacist and prescriber should help resolve these questions before the current supply runs low.

Pirtobrutinib and acalabrutinib prescribing information illustrates the need to consider response, tolerability, monitoring, and accompanying medicines during continuing treatment.[3,4] Improvement in symptoms is not by itself a reason to stop. A newly prescribed anti-infective drug, anticoagulant, or planned procedure should prompt communication with the lymphoma team so that any adjustment is deliberate and documented.

If maintenance infusions remain planned, check whether the local unit has accepted the handover and what assessments it requires beforehand. Agree how delays or infusion reactions will be handled. Evidence such as the LYMA maintenance study concerns a defined treatment population; it does not establish one maintenance duration for every person with mantle cell lymphoma.[5]

Arrange a local response to urgent symptoms

Ask the treating team to write the circumstances that require urgent assessment and discuss them with the local clinician. Record where the patient can obtain help outside routine clinic hours. During anticancer therapy or incomplete immune recovery, infection can become serious quickly. NCI identifies fever and other infection symptoms during treatment as reasons for prompt contact with the medical team.[6]

The patient's particular fever threshold and instructions should be clear in the handover. Severe breathing difficulty, altered awareness, ongoing significant bleeding, or another rapidly worsening problem requires the local emergency pathway. The Chinese center may provide valuable background information, but waiting for its reply must not become a condition for receiving urgent local care.

Bring a concise record of recent treatment names and dates to an urgent assessment, particularly after cellular therapy or transplantation. Report medicines already taken and the actual course of symptoms. A temporary improvement after a fever-reducing medicine does not establish that an infection has been excluded, and changing anticancer treatment independently can complicate assessment.

Transfer the additional plan after CAR-T or transplantation

After CAR-T, lymphoma control and immune recovery are separate concerns. Continuing cytopenias, infection, or other immune problems may still need attention in a patient whose disease is in remission. The original center should specify the laboratory and immune assessments required, preventive medicines that remain prescribed, and the route for reporting recurrent infections or new symptoms.

FDA's Tecartus information describes serious risks that explain why this monitoring matters.[7] The patient's actual product, complications, and recovery determine the follow-up plan. United States product information does not set a universal date on which an international patient can leave China or reduce monitoring.

After transplantation, retain the recovery instructions, transplant type, important complications, and current preventive care. Discharge or permission to travel does not mean that immune function has returned to normal. NCI describes an extended recovery process that differs between individuals.[8] If a local service cannot perform a particular assessment, discuss alternatives with the original center instead of silently omitting it.

Include vaccination and recovery in the discussion

Bring the vaccination history, including any vaccines given since treatment. The ASCO adult cancer vaccination guideline emphasizes treatment-specific planning; transplantation, CAR-T, and B-cell-depleting therapy can affect timing, response, and the need for revaccination.[9] A routine blood count alone does not establish that every vaccine is now appropriate. The oncology and vaccination teams should coordinate the plan, including decisions about live vaccines.

Persistent fatigue deserves assessment even when lymphoma results are reassuring. It may have several contributors and should not automatically be dismissed as anxiety or managed by remaining in bed indefinitely. NCI discusses assessment and individualized approaches to cancer-related fatigue.[10] Describe specific limitations—preparing meals, walking to a shop, or completing a work shift—so that recovery goals match the patient's actual life.

Other late effects depend on treatment exposure and individual risk. Previous therapy can create reasons to review cardiovascular, neurologic, endocrine, or other health concerns, but not every survivor needs every available screening test. Providing the treatment summary helps the local doctor combine ordinary preventive care with the relevant consequences of cancer treatment.[11]

Reassess suspected relapse before arranging another treatment

A new lump or abnormal result should lead to local clinical assessment and any necessary investigation. Share the findings with the Chinese team if another opinion or return visit may be useful. One abnormal marker is not a sufficient basis for ordering the next drug, and anxiety about recurrence is not a reason to repeat every previous test without discussing its purpose.

If further treatment becomes necessary, the previous regimen, duration of response, reason it ended, and current health will matter again. Add the new evidence to the treatment timeline. Decide which assessments or treatments can occur locally and what would justify returning to China. The location of care may change, while the essential requirement remains that the next action has an identified clinician and a reliable route for the patient to obtain help.